Anti-cancer effect of IN-2001 in MDA-MB-231 human breast cancer

Biomolecules and Therapeutics

Volumn 20, Issue 3, 2012, Pages 313-319

  Min, Kyung Nan ^a   Joung, Ki Eun ^a   Kim, Dae Kee ^a   Sheen, Yhun Yhong ^a  

^a Ewha Womans University   (South Korea)

Author keywords

HDAC; IN 2001; MDA MB 231

Indexed keywords

3 (4 DIMETHYLAMINOPHENYL) N HYDROXY 2 PROPENAMIDE; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IN 2001; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PROTEIN EXPRESSION;

EID: 84862664156     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2012.20.3.313     Document Type: Article

References (36)

1. Archer, S. Y., Meng, S., Shei, A. and Hodin, R. A. (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 95, 6791-6796.
2. Banwell, C. M., Singh, R., Stewart, P. M., Uskokovic, M. R. and Campbell, M. J. (2003) Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res. 164, 83-98.
3. Blobel, G. A. (2000) CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 95, 745-755.
4. Bulavin, D. V., Phillips, C., Nannenga, B., Timofeev, O., Donehower, L. A., Anderson, C. W., Appella, E. and Fornace, A. J. Jr. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet. 36, 343-350.
5. Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon- Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A. and Richon, V. M. (2000a) Suberoylanilide hydroxamic acid, an inhibitor of histonedeacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165-5170.
6. Butler, L. M., Higgins, B., Fox, W. D., Agus, D. B., Cordon-Cardo, C. and Scher, H. J. (2000b) Hybrid polar inhibitors of histone deacetylase suppress the growth of the CWR22 human prostate cancer xenograft. Proc. Am. Assoc. Cancer Res. 41, 289.
7. Butler, L. M., Webb, Y., Agus, D. B., Higgins, B., Tolentino, T. R., Kutko, M. C., LaQuaglia, M. P., Drobnjak, M., Cordon-Cardo, C., Scher, H. I., Breslow, R., Richon, V. M., Rifkind, R. A. and Marks, P. A. (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7, 962-970.
8. Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C. and La Thangue, N. B. (2001) Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 3, 667-674.
9. Cress, W. D. and Seto, E. (2000) Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 184, 1-16.
10. David, G., Alland, L., Hong, S. H., Wong, C. W., DePinho, R. A. and Dejean, A. (1998) Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16, 2549-2556.
11. Davis, T., Kennedy, C., Chiew, Y. E., Clarke, C. L. and deFazio, A. (2000) Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 6, 4334-4342.
12. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. and van Kuilenburg, A. B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737-749.
13. Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K. and Benz, C. C. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495-528.
14. Finnin, M. S., Donigian, J. R. and Pavletich, N. P. (2001) Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 8, 621-625.
15. Finzer, P., Kuntzen, C., Soto, U., zur Hausen, H. and Rösl, F. (2001) Inhibitors of histone deacetylasearrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20, 4768-4776.
16. Fournel, M., Trachy-Bourget, M. C., Yan, P. T., Kalita, A., Bonfi ls, C., Beaulieu, C., Frechette, S., Leit, S., Abou-Khalil, E., Woo, S. H., Delorme, D., MacLeod, A. R., Besterman, J. M. and Li, Z. (2002) Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. 62, 4325-4330.
17. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M. and Horinouchi, S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98, 87-92.
18. Glaser, K. B., Staver, M. J., Waring, J. F., Stender, J., Ulrich, R. G. and Davidsen,S. K. (2003) Gene expression profi ling of multiple histone deacetylase (HDAC) inhibitors: defi ning a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163.
19. Göttlicher, M., Minucci, S., Zhu, P., Krämer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G. and Heinzel, T. (2001) Valproicacid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978.
20. Gray, S. G. and Ekström, T. J. (2001) The human histone deacetylase family. Exp. Cell Res. 262, 75-83.
21. Grunstein, M. (1997) Histone acetylation in chromatin structure and transcription. Nature 389, 349-352.
22. Gui, C. Y., Ngo, L., Xu, W. S., Richon, V. M. and Marks, P. A. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101, 1241-1246.
23. Johnstone, R. W. (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug. Discov. 1, 287-299.
24. Johnstone, R. W. and Licht, J.D. (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18.
25. Kouzarides, T. (2000) Acetylation: a regulatory modifi cation to rival phosphorylation? EMBO J. 19, 1176-1179.
26. Krämer, O. H., Göttlicher, M. and Heinzel, T. (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12, 294-300.
27. Marks, P.A., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T. and Kelly, W.K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202.
28. Qui, L., Kelso, M. J., Hansen, C., West, M. L., Fairlie, D. P. and Parson, P. G. (1999) Anti-tumouractivity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 80, 1252-1258.
29. Reynisdóttir, I., Polyak, K., Iavarone, A. and Massagué, J. (1995) Kip/ Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9, 1831-1845.
30. Richon, V. M., Sandhoff, T. W., Rifkind, R. A. and Marks, P. A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10014-10019.
31. Rosato, R. R., Wang, Z., Gopalkrishnan, R. V., Fisher, P. B. and Grant, S. (2001) Evidence of a functional role forthe cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int. J. Oncol. 19, 181-191.
32. Roth, S. Y., Denu, J. M. and Allis, C. D. (2001) Histone acetyltransferases. Annu. Rev. Biochem. 70, 81-120.
33. Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12, 599-606.
34. Vigushin, D. M., Ali, S., Pace, P. E., Mirsaidi, N., Ito, K., Adcock, I. and Coombes, R. C. (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7, 971-976.
35. Vigushin, D. M. and Coombes, R. C. (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13, 1-13.
36. Villar-Garea, A. and Esteller, M. (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer 112, 171-178.